You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 2, 2025

TRIACORT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Triacort, and what generic alternatives are available?

Triacort is a drug marketed by Solvay and is included in one NDA.

The generic ingredient in TRIACORT is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Triacort

A generic version of TRIACORT was approved as triamcinolone acetonide by TARO on October 1st, 1986.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TRIACORT?
  • What are the global sales for TRIACORT?
  • What is Average Wholesale Price for TRIACORT?
Summary for TRIACORT
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 82
Patent Applications: 4,299
DailyMed Link:TRIACORT at DailyMed
Drug patent expirations by year for TRIACORT

US Patents and Regulatory Information for TRIACORT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Solvay TRIACORT triamcinolone acetonide CREAM;TOPICAL 087113-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

TRIACORT Market Analysis and Financial Projection

Triamcinolone Market Dynamics and Financial Trajectory

Market Introduction and Definition

Triamcinolone, a potent corticosteroid, is widely used to manage and alleviate the symptoms of various chronic inflammatory diseases. The global triamcinolone market is driven by several key factors, including the increasing prevalence of chronic diseases, the rise in geriatric population, and advancements in healthcare infrastructure.

Market Size and Growth

The global triamcinolone market was valued at $0.9 billion in 2023 and is projected to reach $1.3 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 3.8% from 2024 to 2033[1].

Key Drivers of Market Growth

Increasing Prevalence of Chronic Diseases

The rise in chronic inflammatory diseases such as asthma, arthritis, and allergies significantly contributes to the growth of the triamcinolone market. These conditions are becoming more common due to factors like aging populations, unhealthy lifestyles, and environmental changes. Triamcinolone's anti-inflammatory and immunosuppressive properties make it a frequently prescribed treatment for these chronic conditions[1].

Rise in Geriatric Population

The global population is aging, leading to an increase in age-related chronic and inflammatory diseases. Elderly individuals are more prone to conditions like arthritis, asthma, and various dermatological disorders due to the natural decline in immune function and cumulative wear and tear on the body's systems. This demographic shift is expected to significantly contribute to the growth of the triamcinolone market[1].

Expansion of Healthcare Infrastructure

Advanced healthcare systems, particularly in regions like North America, and increasing healthcare expenditure in countries such as China, Japan, and India, are driving the market growth. Improved medical infrastructure and rising awareness about chronic diseases and their treatments also play crucial roles[1].

Regional Market Dynamics

North America

North America dominated the triamcinolone market share in 2023, primarily due to the high prevalence of chronic conditions and significant investment in research and development. The U.S. is a major contributor to this dominance, with a large patient population and widespread access to healthcare services[1].

Asia-Pacific

The Asia-Pacific region is experiencing rapid growth in the triamcinolone market. This expansion is fueled by rising healthcare expenditure, improving medical infrastructure, and increasing awareness about chronic diseases. Countries like China, Japan, and India are at the forefront of this growth, driven by large populations and developing healthcare systems[1].

Prescription Data and Market Share

Key Market Players

Major players operating in the triamcinolone market include Novartis AG, Mylan N.V., Lupin, Teva Pharmaceuticals, Akorn Inc, Cosette Pharmaceuticals, Inc, Bristol Myers Squibb Company, Glenmark Pharmaceuticals, Taro Pharmaceutical Industries, and Sun Pharmaceutical Industries Limited. These companies play a significant role in driving market growth through their extensive product portfolios and strong distribution networks[1].

Product Offerings

Pacira BioSciences, for instance, has expanded its product offerings to include ZILRETTA (triamcinolone acetonide extended-release injectable suspension) after acquiring Flexion Therapeutics in November 2021. ZILRETTA has been performing well and is in the early stages of its growth trajectory[2].

Financial Performance and Projections

Current Market Value

The global triamcinolone market was valued at $0.9 billion in 2023. This valuation reflects the current demand for triamcinolone driven by its widespread use in managing chronic inflammatory diseases[1].

Projected Market Value

The market is projected to reach $1.3 billion by 2033, indicating a steady growth trajectory over the next decade. This growth is supported by the increasing prevalence of chronic diseases and the expanding geriatric population[1].

Revenue Growth Rate

The market is expected to grow at a CAGR of 3.8% from 2024 to 2033. This growth rate is moderate but consistent, reflecting the stable demand for triamcinolone in the healthcare sector[1].

Impact of Healthcare Expenditure

Global Healthcare Spending

The rise in healthcare expenditure globally, particularly in countries like Germany where healthcare spending rose to about 13.2% of GDP in 2021, supports the growth of the triamcinolone market. Increased spending on healthcare infrastructure and services enhances access to treatments like triamcinolone[1].

Challenges and Opportunities

Trade-Off Between Innovation and Affordability

The pharmaceutical industry faces a trade-off between establishing incentives for innovation and ensuring affordability of drugs. High drug prices can strain consumer and taxpayer ability to afford treatments, while controlling prices can reduce pharmaceutical industry revenues and potentially lead to fewer new drugs being developed[3].

Biosimilar Market Impact

The biosimilar market, although not directly related to triamcinolone, influences the broader pharmaceutical landscape. Biosimilars have led to significant price decreases over time, which can impact the pricing strategies of branded drugs like triamcinolone. However, triamcinolone, being a small molecule drug, is less likely to be directly affected by biosimilar competition[4].

Market Feedback and Clinical Developments

Clinical Trials and Product Development

Companies like Pacira BioSciences are actively involved in clinical trials and product development to expand the use of triamcinolone and other related products. For example, Pacira is advancing a pipeline of new growth opportunities, including Phase 3 studies for EXPAREL, which, although not directly related to triamcinolone, indicates the ongoing research and development efforts in the pain management and anti-inflammatory drug sectors[2].

Key Takeaways

  • The global triamcinolone market is valued at $0.9 billion in 2023 and is projected to reach $1.3 billion by 2033.
  • The market is driven by the increasing prevalence of chronic diseases, the rise in geriatric population, and advancements in healthcare infrastructure.
  • North America dominates the market, with significant contributions from the U.S.
  • The Asia-Pacific region is experiencing rapid growth due to rising healthcare expenditure and improving medical infrastructure.
  • Major players include Novartis AG, Mylan N.V., and Bristol Myers Squibb Company, among others.
  • The market faces challenges related to the trade-off between innovation and affordability, but ongoing research and development efforts support its growth.

FAQs

What is the current market size of the triamcinolone market?

The global triamcinolone market was valued at $0.9 billion in 2023[1].

What is the projected market size of the triamcinolone market by 2033?

The market is projected to reach $1.3 billion by 2033[1].

What is the growth rate of the triamcinolone market?

The market is expected to grow at a CAGR of 3.8% from 2024 to 2033[1].

Which region dominates the triamcinolone market?

North America, particularly the U.S., dominates the triamcinolone market[1].

What are the key drivers of the triamcinolone market growth?

The key drivers include the increasing prevalence of chronic diseases, the rise in geriatric population, and advancements in healthcare infrastructure[1].

Who are the major players in the triamcinolone market?

Major players include Novartis AG, Mylan N.V., Lupin, Teva Pharmaceuticals, and Bristol Myers Squibb Company, among others[1].

Sources

  1. Allied Market Research, "Triamcinolone Market Statistics, Trends | Forecast - 2033"
  2. Pacira BioSciences, "Pacira BioSciences Reports Preliminary Net Product Sales of $50.2 Million for July 2022"
  3. Brookings, "Addressing the Trade-Off Between Lower Drug Prices and Incentives for Pharmaceutical Innovation"
  4. Samsung Bioepis, "Biosimilar Market Report - SAMSUNG BIOEPIS"

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.